Companies › Sinovac Life Sciences
3 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 1, 1 Phase 3; Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sinovac PCV13 13-valent pneumococcal conjugate vaccine | – | Phase 3 | Pneumococcal Infectious Disease | – |
| Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) Hexavalent reassortant rotavirus attenuated live vaccine | – | Phase 2 | Rotavirus Gastroenteritis | Nov 2026 |
| Sinovac PCV24 24-valent pneumococcal conjugate vaccine | – | Phase 2 | Pneumococcal Infectious Disease | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06617715 | Sinovac PCV13 | Phase 3 | Pneumococcal Infectious Disease | Infectious disease | May 2026 |
| NCT06800261 | Sinovac PCV24 | Phase 1 | Pneumococcal Infectious Disease | Infectious disease | Jun 2026 |
| NCT06967272 | Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) | Phase 2 | Rotavirus Gastroenteritis | Infectious disease | Nov 2026 |
| NCT06967272 | Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) | Phase 2 | Rotavirus Gastroenteritis | Infectious disease | Nov 2026 |
| NCT07300644 | Sinovac PCV24 | Phase 2 | Pneumococcal Infectious Disease | Infectious disease | Dec 2027 |
No annotated target.
–
Bharat Biotech International Green Cross Bavarian Nordic Osivax Artcline
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.